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[word count limit: 250 words (structured); current count: 250] 74 
ABSTRACT 75 
Context: Long-term data on enzyme replacement treatment of hypophosphatasia 76 
(HPP) are limited. 77 
Objective: To evaluate efficacy and safety of asfotase alfa in patients aged ≤5 years 78 
with HPP followed for up to 6 years. 79 
Design: Phase 2 open-label study (July 2010–September 2016). 80 
Setting: 22 sites, 12 countries. 81 
Participants: Sixty-nine patients (median [range] age : 16.0 [0.02–72] mo) with severe 82 
HPP and sign/symptom-onset before age 6 months. 83 
Intervention: Asfotase alfa 2 mg/kg 3 times/wk or 1 mg/kg 6 times/wk subcutaneously.  84 
Main Outcome Measures: Primary efficacy measure: Radiographic Global Impression 85 
of Change (RGI-C) score (−3 [severe worsening] to +3 [complete/near-complete 86 
healing]). Additional outcome measures: respiratory status, growth, safety. Post hoc 87 
analysis: characteristics of radiographic “responders” vs. “nonresponders” at Year 1 88 
(RGI-C: ≥+2 vs. <+2). 89 
Results: During median (min, max) 2.3 (0.02, 5.8) years of treatment, RGI-C scores 90 
improved significantly at Month 6 (+2.0 [−1.7, +3.0]), Year 1 (+2.0 [−2.3, +3.0]), and Last 91 
Assessment (+2.3 [−2.7, +3.0]; P<.0001 all). Of 24 patients requiring respiratory support 92 
at Baseline, 11 (46%) no longer needed support. Height/weight Z-scores generally 93 
increased. Nine patients died (13%). All patients experienced 1 adverse event; pyrexia 94 
was most common. Compared with “responders” (n=50 [72%]), “nonresponders” (n=19 95 
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[28%]) had more severe disease at Baseline and a higher rate of neutralizing antibodies 96 
at Last Assessment. 97 
Conclusions: Most infants/young children treated with asfotase alfa showed early 98 
radiographic and clinical improvement that was sustained up to 6 years; radiographic 99 
“nonresponders” had more severe underlying disease and more frequent neutralizing 100 
antibodies at Last Assessment. 101 
 102 
[Character limit: 200 (including spaces); current count: 195] 103 
Précis  104 
Most infants and young children with hypophosphatasia treated with asfotase alfa 105 
showed improved skeletal manifestations, respiratory function, and growth within 1 year, 106 
maintained up to 6 years. 107 
  108 
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[word count limit: none; current count: 4793] 109 
INTRODUCTION 110 
Hypophosphatasia (HPP) is the rare, inherited, systemic, metabolic disease 111 
characterized by low activity of the tissue-nonspecific isoenzyme of alkaline 112 
phosphatase (TNSALP), which leads to extracellular accumulation of its substrates, 113 
mainly inorganic pyrophosphate (PPi) and pyridoxal 5'-phosphate (PLP) (1-4). 114 
Increased extracellular levels of PPi inhibit bone mineralization and lead to impaired 115 
skeletal mineralization in affected patients and additional rickets-like deformities in 116 
infants and children (2,4). Reduced dephosphorylation of PLP, the circulating form of 117 
vitamin B6, by TNSALP has been associated with vitamin B6-responsive seizures in 118 
infants with HPP (3,5). 119 
 120 
Clinical presentation of HPP varies with age at onset, from in utero to adulthood (2,6). 121 
Characteristic signs, symptoms, and complications of perinatal and infantile HPP that 122 
are potentially life-threatening include respiratory failure, vitamin B6-responsive 123 
seizures, chest deformity, and craniosynostosis; other manifestations include severe 124 
hypercalcemia, nephrocalcinosis, poor growth, osteomalacia, and bowing of the long 125 
bones (2,5,7-11). Historically, patients with perinatal and infantile HPP have 58% to 126 
100% mortality during the first year of life (12-14). The most common cause of death 127 
among infants with HPP is respiratory failure secondary chest deformity and pulmonary 128 
hypoplasia (12,15). 129 
 130 
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Asfotase alfa (Strensiq®; Alexion Pharmaceuticals, Inc., Boston, MA, USA) is a human 131 
recombinant TNSALP enzyme replacement therapy approved for patients with pediatric-132 
onset HPP (16). In an open-label study of 11 infants and young children (aged ≤3 y) 133 
with life-threatening HPP, treatment with asfotase alfa for up to 7 years improved HPP-134 
related skeletal abnormalities seen on radiograph, respiratory function, growth, and 135 
cognitive and motor function (17,18). Here we report the long-term safety and efficacy of 136 
asfotase alfa in the largest study to date of infants and children aged ≤5 years with 137 
manifestations of HPP before age 6 months. 138 
 139 
MATERIALS AND METHODS 140 
Patients 141 
Children aged ≤5 years with signs or symptoms of HPP before age 6 months were 142 
eligible for enrollment if they had a documented diagnosis of HPP. Diagnosis of HPP 143 
required the following: total serum alkaline phosphatase (ALP) activity below the lower 144 
limit of normal for age, plasma PLP above the upper limit of normal (unless the patient 145 
was receiving pyridoxine for seizures), radiographic evidence of HPP (flared and frayed 146 
metaphyses, widened growth plates, areas of radiolucency or sclerosis, or severe, 147 
generalized osteopenia), and ≥2 HPP-related findings (history or presence of 148 
nontraumatic postnatal fracture and/or delayed fracture healing, nephrocalcinosis or 149 
history of elevated serum calcium, functional craniosynostosis, respiratory compromise 150 
or rachitic chest deformity, vitamin B6-responsive seizures, or failure to thrive). 151 
Exclusion criteria were serum calcium or phosphate levels below the normal range, 152 
serum 25(OH) vitamin D levels <20 ng/mL, current evidence of a treatable form of 153 
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rickets, prior treatment with bisphosphonates, investigational drug treatment within 1 154 
month, or current enrollment in any other study involving a new drug, device, or 155 
treatment for HPP. 156 
 157 
The study complied with the Declaration of Helsinki and International Conference on 158 
Harmonisation Guideline for Good Clinical Practice and with national, state, and local 159 
laws of pertinent regulatory authorities. The protocol was approved by each site’s 160 
institutional review board/independent ethics committee, and written informed consent 161 
was obtained for all patients from a parent(s) or guardian(s). 162 
 163 
Study Design 164 
In this open-label, multicenter, single-arm, multinational study (ClinicalTrials.gov 165 
NCT01176266; EUDRACT 2010-019850-42), eligible patients received a total 166 
subcutaneous dose of 6 mg/kg/wk of asfotase alfa administered as 1 mg/kg 6 times per 167 
week or 2 mg/kg 3 times per week (maximum volume: 1 mL asfotase alfa per injection). 168 
Dose adjustments were allowed at the investigator’s discretion to account for changes 169 
in body weight or in consultation with the medical monitor for safety concerns or lack of 170 
efficacy. The maximum dose permitted was 40 mg per injection or 9 mg/kg/wk in 171 
Australia, France, Germany, Italy, Saudi Arabia, Spain, and the United Kingdom per 172 
protocol amendment; no dose restrictions were applied in Canada, Japan, Russia, 173 
Turkey, or the United States. The initial dose of asfotase alfa was administered at the 174 
study site during the Baseline visit; post-Baseline injections could be administered at 175 
home by a parent, legal guardian, or designee after adequate training. With each 176 
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injection, the designated individual was required to complete a worksheet regarding the 177 
patient’s health condition, any new medications, and details of the injection. Study visits 178 
were scheduled at Weeks 3 and 6, Months 3, 6, 9, 12, 15, 18, and 24, and every 6 179 
months thereafter until the end-of-study assessment (Month 48 in patients enrolled in 180 
the United Kingdom and final every-6-month assessment in other countries). Patients 181 
were enrolled starting July 22, 2010, and the last patient completed the study 182 
September 26, 2016. 183 
 184 
Outcomes Measures  185 
Primary efficacy measure 186 
The primary efficacy measure was improvement of HPP-related skeletal manifestations 187 
at Week 24 (Month 6) and Week 48 (Year 1) of treatment as measured on the 188 
Radiographic Global Impression of Change (RGI-C) scale (19). The RGI-C (19) is a 189 
validated 7-point scale that assesses changes from Baseline in HPP-related skeletal 190 
abnormalities: −3=severe worsening, −2=moderate worsening, −1=minimal worsening, 191 
0=no change, +1=minimal healing, +2=substantial healing, and +3=complete or near 192 
complete healing. Radiographs of the chest, bilateral wrists, and bilateral knees were 193 
reviewed by 3 independent pediatric radiologists, and comparisons with Baseline were 194 
scored. The mean RGI-C score for each patient at each time point was calculated from 195 
available scores. The radiologists were blinded to post-Baseline timepoints and all other 196 
patient information. 197 
 198 
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Secondary efficacy measures  199 
Skeletal manifestations of HPP over time: RGI-C scores and change from Baseline in 200 
Rickets Severity Scale (RSS) (20) scores were assessed at all study visits starting at 201 
Month 3. The RSS (20) is a 10-point scale (0=absence of metaphyseal cupping and 202 
fraying [both characteristic of rickets] to 10=severe rickets; maximum of 4 points for the 203 
wrists and 6 points for the knees) originally developed to assess the severity of 204 
nutritional rickets in the wrists and knees. Radiographs for determination of RSS score 205 
were read by a single independent rater who developed the RSS (Tom D. Thacher, 206 
MD). The percentage of “responders” (individual mean RGI-C score: ≥+2) at each study 207 
visit was also determined. 208 
 209 
Respiratory status: Respiratory status (including use and type of support) was assessed 210 
at Screening, Baseline, and all subsequent study visits. 211 
 212 
Growth: Length/height, weight, and head circumference were recorded during physical 213 
examinations at required study visits to assess changes in growth. Length/height and 214 
weight Z-scores were assigned based on the Centers for Disease Control and 215 
Prevention growth charts for age- and sex-matched healthy infants and children (21). 216 
Head circumference Z-scores were calculated using World Health Organization 217 
formulae (22). 218 
 219 
Ventilator-free and overall survival: Ventilator-free survival was assessed with the 220 
occurrence of death and ventilatory support (continuous positive airway pressure 221 
12 
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[CPAP], bilevel or biphasic positive airway pressure, or mechanical ventilation [invasive 222 
ventilation via endotracheal intubation or tracheostomy]). Supplemental oxygen was 223 
considered respiratory but not ventilatory support. Survival was monitored throughout 224 
the study. 225 
 226 
Other measures  227 
Blood samples were collected to assess serum ALP activity, plasma PPi and PLP, and 228 
serum parathyroid hormone (PTH) concentrations at required study visits after an 229 
overnight fast and before study drug administration. 230 
 231 
ALPL gene mutation analysis for patients not previously tested was performed by 232 
Connective Tissue Gene Tests (Allentown, PA, USA). 233 
 234 
Safety and tolerability 235 
Safety was assessed by routine reporting of adverse events (AEs), which included 236 
serious AEs, injection site reactions (ISRs), and injection-associated reactions (IARs). 237 
ISRs were defined as treatment-emergent AEs (TEAEs) that were localized to the site 238 
of study drug administration, occurred at any time point after study drug initiation, and 239 
were assessed by the investigator as possibly, probably, or definitely related to study 240 
drug. IARs were defined as systemic signs, symptoms, or findings that occurred within 3 241 
hours after study drug administration and were assessed by the investigator as 242 
possibly, probably, or definitely related to study drug. AEs of special interest included 243 
ectopic calcifications, lipodystrophy, craniosynostosis, and chronic hepatitis and were 244 
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based on clinical review of observed AEs. Additional safety assessments included 245 
physical examinations, clinical laboratory tests (including calcium and magnesium), 246 
anti–asfotase alfa antibody levels (PPD Laboratories, LLC, Richmond, VA, USA), 247 
fundoscopic eye examinations, and renal ultrasounds. The clinical significance of 248 
abnormal laboratory findings was judged by the investigator. Safety events reported 249 
after the study ended were not included. 250 
 251 
“Responder” analysis 252 
A post hoc analysis compared Baseline characteristics of “responders” by radiography 253 
(RGI-C score: ≥+2) with those of “nonresponders” (score: <+2) at Year 1 of treatment.  254 
 255 
Statistical analysis 256 
All efficacy and safety analyses were performed on the full analysis population (patients 257 
who received ≥1 dose of asfotase alfa). Some analyses were repeated on the per 258 
protocol population (patients who received any asfotase alfa and had no major protocol 259 
deviations that could influence treatment effect). In general, continuous variables were 260 
summarized descriptively (data reported herein are median [minimum, maximum] 261 
unless otherwise specified), and categorical variables were summarized by counts and 262 
percentages of patients. 263 
 264 
For the primary efficacy analysis (RGI-C scores at Month 6 and Year 1), a 265 
nonparametric Wilcoxon signed-rank test was used to determine whether the median 266 
RGI-C scores at Month 6 and Year 1 differed from 0. Missing values were imputed 267 
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using last observation carried forward. Patients with no recorded post-Baseline values 268 
were assigned as having no change (score: 0). 269 
 270 
Secondary efficacy analyses of RGI-C scores, percent of “responders,” and change 271 
from Baseline in RSS scores at each study visit were conducted in a manner similar to 272 
that used for the primary analysis; however, only observed data were used (no 273 
imputation). P values for length/height and weight Z-scores were calculated post hoc 274 
using the nonparametric Wilcoxon signed-rank test comparing median change to 0. 275 
Pharmacodynamic and safety assessments are summarized descriptively. Ventilator-276 
free survival and overall survival time were assessed using Kaplan-Meier methodology. 277 
 278 
For the post hoc “responder” analysis, P values were calculated using the exact 279 
Wilcoxon rank-sum test for continuous variables and the Fisher’s exact test for 280 
categorical variables. Missing values at Year 1 were imputed with last observation 281 
carried forward. Patients with no post-Baseline data were assigned as having no 282 
change (score: 0) and considered “nonresponders.” 283 
 284 
RESULTS 285 
Patients 286 
In total, 69 patients were enrolled from 22 sites in 12 countries and were included in the 287 
full analysis population, and 57 were included in the per protocol population (Figure 1). 288 
Patients were excluded from the per protocol population if they did not meet entry 289 
criteria or violated entry criteria (n=9), if they deviated from study protocol procedures 290 
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(n=2), if study drug was administered incorrectly (n=2) or not at all (n=1), or if an 291 
assessment/procedure was not done (n=1) (Figure 1). The number of patients enrolled 292 
in each country was as follows: Australia (n=1), Canada (n=11), France (n=5), Germany 293 
(n=13), Italy (n=2), Japan (n=5), Saudi Arabia (n=1), Russia (n=1), Spain (n=1), Turkey 294 
(n=4), United Kingdom (n=4), and United States (n=21). Baseline demographic and 295 
clinical characteristics are summarized in Table 1. 296 
 297 
Dosing 298 
Nearly all patients (67/69 [97%]) started asfotase alfa at 6 mg/kg/wk, with 64 (96%) 299 
receiving 2 mg/kg 3 times per week and 3 (4%) receiving 1 mg/kg 6 times per week. 300 
One patient started at 2 mg/kg 7 times per week and another started at 3 mg/kg 3 times 301 
per week. Doses were increased or decreased to 3–28 mg/kg/wk for 17/69 (25%) 302 
patients to account for changes in body weight, to enhance the likelihood of a clinical 303 
response, or because of AEs and administration issues (volume and number of 304 
injections). 305 
 306 
Overall, median treatment duration was 2.3 (0.02, 5.8) years. Of the 69 patients in the 307 
full analysis population, 3 (4%) received treatment for <3 months and 14 (20%) for ≥36 308 
months. 309 
 310 
Primary efficacy measure  311 
At Month 6 of treatment, the median (min, max) RGI-C score indicated significant 312 
improvement (+2.0 [−1.7, +3.0]; P<.0001; n=69); most patients (40/69 [58%]) were 313 
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considered “responders,” and 6 (9%) achieved a score of +3, indicating “complete or 314 
near complete healing” of HPP-related skeletal manifestations. Results observed at 315 
Month 6 were consistent with those at Year 1 (+2.0 [−2.3, +3.0]; P<.0001; n=69); 50/69 316 
(72%) patients were considered “responders,” of which 4 (6%) achieved a score of +3. 317 
Results were similar in the per protocol population (data not shown). 318 
 319 
Secondary efficacy measures 320 
Skeletal manifestations of HPP over time: Preliminary patient-level radiographic 321 
outcomes have been published (14). Significant (P<.05) improvements in RGI-C score 322 
were observed at Months 3 and 6, Years 1, 2, 3, 4, and 5, and Last Assessment 323 
(Figure 2). The proportion of patients classified as “responders” (RGI-C score ≥+2) 324 
increased during the study, from 36% (24/66 patients) at Month 3 to 73% (49/67 325 
patients) at Last Assessment. Consistent with RGI-C scores, RSS scores improved 326 
significantly (P<.05) from Baseline at Months 3 and 6, Years 1, 2, 3, 4, and 5, and Last 327 
Assessment (Figure 3). Results were similar in the per protocol population (data not 328 
shown). 329 
 330 
Respiratory status: Of the 45/69 (65%) patients who did not require respiratory support 331 
at Baseline, 38 (84%) lived without support during the study and 43 (96%) did not 332 
require support at the Last Assessment; 1 patient was receiving supplemental oxygen at 333 
Year 4, and 1 was receiving CPAP at Month 6. Three patients developed the need for 334 
respiratory support after Baseline but were weaned before Last Assessment (by Month 335 
9, Year 1.5, and Year 2.5). Of the 24/69 (35%) patients who did require respiratory 336 
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support at Baseline (including invasive mechanical ventilation, CPAP, or supplemental 337 
oxygen), 11 (46%) no longer required support at Last Assessment. 338 
 339 
Growth: Length/height and weight Z-scores generally improved over time (Figure 4). 340 
Change from Baseline at Last Assessment was significant for both length/height (0.5 341 
[−4, 4]; n=66; P=.0025) and weight (1.0 [−5, 6]; n=67; P=.0001) Z-scores. Baseline head 342 
circumference Z-score was −1.0 (−4, 4; n=56); change from Baseline was 0.1 (−2, 3; 343 
n=47) at Month 6 and 0.2 (−3, 7; n=55) at Last Assessment. 344 
 345 
Ventilator-free and overall survival: Thirty-eight of the 45 patients (84%) who were not 346 
receiving respiratory support at Baseline remained ventilator-free. The Kaplan-Meier 347 
estimate of the ventilator-free survival rate at Year 6 for these patients was 84%. Among 348 
all 69 patients, the Kaplan-Meier estimate of the overall survival rate at Year 6 was 349 
80%. Survival outcomes for patients in this study were also included in a published 350 
analysis that pooled these data with those of a separate study (14). 351 
 352 
Other measures  353 
Median (min, max) ALP activity increased from 20 (18, 122) U/L at Baseline (n=65) to 354 
3761 (272, 11,910) U/L after 3 weeks of treatment (n=61) and continued to increase 355 
through Year 1 (6742 [1315, 20,041] U/L; n=49). ALP remained elevated throughout 356 
treatment, as expected with asfotase alfa treatment. Median (min, max) PPi 357 
concentration, which was elevated at Baseline (6.3 [2.7, 13.3] µM; n=65), decreased to 358 
within reference range (1.3–5.7 µM) at Week 6 (3.9 [0.8, 39.2] µM) and remained within 359 
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reference range throughout the study. Similarly, median (min, max) PLP concentration 360 
decreased from Baseline (521 [48, 24,600] ng/mL; n=60) to within reference range 361 
(11.8–68.4 ng/mL) at Week 6 (44 [6, 4590] ng/mL) and remained within reference range 362 
through Year 5. PTH levels were 1.2 (0.6, 6.7; n=48) pmol/L at Baseline, 1.7 (0.6, 45.9; 363 
n=52) pmol/L at Month 6, and 2.2 (0.6, 10.1; n=66) pmol/L at Last Assessment. 364 
 365 
Sixty-two patients had ALPL mutation analysis results; 44 patients were compound 366 
heterozygous for 2 pathogenic mutations, 9 were homozygous for the same mutant 367 
allele, and 9 had only 1 mutation identified consistent with a dominant-negative effect. 368 
 369 
Safety and tolerability 370 
All patients experienced 1 treatment-emergent AE (TEAE). Table 2 summarizes the 371 
most common TEAEs occurring in 20% of patients, regardless of relationship to study 372 
drug. Most TEAEs were mild (2125/3052 [70%]) or moderate (728/3052 [24%]) in 373 
severity and assessed by the investigator as unrelated to study drug (2409/3052 [79%]). 374 
The most common TEAEs assessed as related to study drug were ISRs (593/643 375 
[92%]) and IARs (11/643 [2%]), which occurred in 43 and 6 patients, respectively. The 376 
most common ISRs were injection site erythema (33/69 [48%]), discoloration (12/69 377 
[17%]), induration (11/69 [16%]), and hematoma (10/69 [15%]). IARs consisted of 378 
pyrexia (4/69 [6%]), chills (1/69 [1%]), injection site rash (1/69 [1%]), anaphylactoid 379 
reaction (1/69 [1%]), drug hypersensitivity (1/69 [1%]), and papular rash (1/69 [1%]). 380 
The IARs of anaphylactoid reaction (categorized as stage 1 anaphylactic shock) 381 
and drug hypersensitivity were considered serious; neither patient had received 382 
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pretreatment with medications to manage IARs. Both events resulted in 383 
interruption of asfotase alfa administration; the anaphylactoid reaction was 384 
treated with an IV electrolyte solution, and no treatment was given for the event of 385 
drug hypersensitivity. Both events resolved, and treatment with asfotase alfa was 386 
restarted without further occurrences. 387 
Lipodystrophy was reported in 5/69 (7%) patients and was mild or moderate in severity 388 
and assessed as probably related or related to study drug. Eight patients (8/69 [12%]) 389 
had ectopic calcification findings on eye examination, which were identified as TEAEs in 390 
2 patients. Both events involved corneal deposits, were considered unrelated to study 391 
drug and did not interfere with vision, and resolved at Last Assessment. 392 
Nephrocalcinosis was reported in 46/69 (67%) patients and was present at Baseline in 393 
all but 6 patients. Five patients had nephrocalcinosis reported as a TEAE. An additional 394 
7 had 8 TEAEs that were not recorded as ectopic calcifications or nephrocalcinosis but 395 
were considered as such upon medical review. Renal function remained normal in all 396 
patients. 397 
 398 
A total of 28/69 (41%) patients experienced 46 AEs relevant to the AE of 399 
craniosynostosis (onset after start of treatment: 1–1851 d); all but 3 events were 400 
assessed as unlikely related or unrelated to study drug, and all but 7 were mild or 401 
moderate in severity. Two patients required surgical treatment. 402 
 403 
Twenty-two events related to chronic hepatitis were reported in 13/69 (19%) patients. All 404 
were mild or moderate in severity. Hepatomegaly in 1 patient was assessed as possibly 405 
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related to study drug treatment. A serious AE of increased hepatic enzymes in another 406 
patient was moderate in severity and assessed as unlikely related to study drug. 407 
 408 
A total of 50/69 (72%) patients experienced 297 serious AEs, most of which (286 [96%]) 409 
were assessed by the investigator as unlikely related or unrelated to study drug. Of the 410 
11 serious AEs considered treatment related, 7 were ISRs or IARs in 3 patients; the 411 
remaining 4 occurred in 3 patients: craniosynostosis (n=1), pneumonia resulting in study 412 
drug withdrawal (n=1), and Arnold-Chiari type 1 malformation and syringomyelia (n=1). 413 
 414 
In total, 9 patients (13%) died. The causes of death in 6 patients were respiratory failure 415 
and cerebral death (following findings of hypoxia-induced lesions/encephalopathy 1 416 
week prior to death); HPP-related complications; severe respiratory failure; 417 
cardiopulmonary arrest; severe cardiopulmonary insufficiency; and transtentorial and 418 
cerebellar tonsillar herniation due to cerebral edema related to severe HPP. Three 419 
patients died of pneumonia; in 1 patient, pneumonia was considered possibly related to 420 
asfotase alfa treatment. 421 
 422 
Calcium and magnesium levels were of particular interest in this study population based 423 
on their role in bone formation, strength, and rigidity. The mean calcium level was within 424 
normal limits at Baseline (mean [SD]: 2.6 [0.3] mmol/L), and only small fluctuations were 425 
observed over the course of the study. Post-Baseline changes in calcium levels were 426 
considered clinically significant by the investigator in 6 patients; 3 patients had elevated 427 
levels (3.6 mmol/L at Week 3 [n=1]; 3.6 mmol/L at Week 3 and 3.3 mmol/L at Week 6 428 
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[n=1]; and 3.1 mmol/L at Week 120 [n=1]), of which 2 had elevated levels at Baseline, 429 
and 3 had decreased levels (2.1 mmol/L at Month 3 [n=1; age at Baseline: 217 wk]; 2.0 430 
mmol/L at Month 9 [n=1; age at Baseline: 21 wk]; and 2.2 mmol/L at Year 1 [n=1; age at 431 
Baseline: 4 wk]). Magnesium levels remained generally within normal range; 1 patient 432 
had a clinically significantly low level at Month 3 (0.5 mmol/L) that was normalized at 433 
Months 6 and 9 (Last Assessment). 434 
 435 
Twelve patients had clinically significantly abnormal hematology findings. Five had low 436 
hematocrit and hemoglobin levels, 5 had high leukocyte or lymphocyte counts, 1 had 437 
low neutrophil count, and 1 had high blasts. For most patients, hematology findings 438 
returned to normal or were no longer considered clinically significant at the patient’s 439 
Last Assessment; 1 patient had clinically significantly low hematocrit, hemoglobin, and 440 
erythrocyte levels at Years 3.5 and 4 (Last Assessment). 441 
 442 
Anti–asfotase alfa antibody levels 443 
In total, 60/68 (88%) patients tested positive for anti–asfotase alfa antibodies during the 444 
study (maximum titer: 2048); 40 (67%) of these patients tested positive for neutralizing 445 
antibodies (NAbs). Six patients tested positive for anti–asfotase alfa antibodies at 446 
Baseline, 1 of whom tested negative at all subsequent assessments. The median (min, 447 
max) positive NAb titer at Last Assessment, measured as percent inhibition, was 7.7% 448 
(4.5, 92.6). Median (min, max) time to detection of first post-Baseline NAb titer was 449 
168.5 (20, 1359) days. No clear relationship was found between the presence of anti–450 
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asfotase alfa antibodies and AEs, nor were any AEs suggestive of immune mediation or 451 
tachyphylaxis. 452 
 453 
RGI-C “Responders” 454 
Results of the post hoc comparison between RGI-C “responders” (individual mean ≥+2 455 
at Year 1) and “nonresponders” at Week 48 are summarized in Table 3. Of the 69 456 
patients in this study, 50 (72.5%) of patients had an RGI-C score of ≥+2 at Year 1. 457 
Nineteen patients did not achieve an RGI-C score of ≥+2 at Year 1; median RGI-C 458 
score for these “nonresponders” was 0.67 at Year 1. Seventeen of these 459 
“nonresponders” had a last overall on-treatment assessment, and of these, 5 achieved 460 
a RGI-C score of ≥+2 by approximately 2.3 years. In this same timeframe, an additional 461 
4 “nonresponders” achieved a RGI-C score between +1 and <+2. The remaining 8 462 
“nonresponders” had RGI-C scores <+1 at Last Assessment. 463 
 464 
A greater proportion of “responders” than “nonresponders” completed the study (94% 465 
vs. 68%, respectively; P=.0105), with fewer deaths (4% vs. 37%, respectively; 466 
P=.0012). Compared with “responders,” “nonresponders” also had higher serum 467 
calcium (P=.0204), plasma PLP (P=.0403), and plasma PPi concentrations (P=.0427) at 468 
Baseline. “Nonresponders” had lower length/height Z-scores (P=.0345) and smaller 469 
chest circumferences (P=.0261) at Baseline than “responders.” Correlation between 470 
Baseline ALP activity and RGI-C score at Year 1 was moderate in “nonresponders” 471 
(Pearson correlation coefficient: 0.5468; P=.0189) and weak in “responders” (0.2008; 472 
P=.1759). There was no statistical difference between “responders” and 473 
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“nonresponders” in anti–asfotase alfa antibody status during the study. Positive NAb 474 
status was not statistically significantly different between “responders” and 475 
“nonresponders” at Month 6 or at Year 1, but the percentage of “nonresponders” 476 
positive for NAbs was significantly higher (9/19; 60%) than the percentage of 477 
“responders” (9/50; 20%; P=.0047) at Last Assessment. 478 
 479 
DISCUSSION 480 
This open-label study of asfotase alfa treatment in infants and young children with a 481 
follow-up period of up to 6 years is the largest, prospective clinical study of HPP to date. 482 
The enrolled population of 69 children with severe HPP is exceptionally large for a study 483 
of a rare disease such as HPP. This study assessed therapy response, showing that 484 
asfotase alfa was efficacious and safe in the majority of children who had onset of 485 
severe HPP signs/symptoms before age 6 months. Improvements in skeletal 486 
manifestations, respiratory support, and growth were observed during treatment with 487 
asfotase alfa within 6 months and were sustained for a median of 2.3 years and up to 6 488 
years of treatment. Radiographic “nonresponders” at Year 1 generally had more severe 489 
disease at Baseline, and a higher incidence of positive NAb status at study end than 490 
“responders.” 491 
 492 
The primary efficacy measures at Month 6 and Year 1 were met, showing significant 493 
improvements in HPP-related skeletal manifestations. Moreover, 58% of patients were 494 
considered “responders” at Month 6 and 72% at Year 1, indicating substantial healing of 495 
skeletal manifestations. Improvements in respiratory status were also observed; nearly 496 
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half (46%) the patients who started the study requiring respiratory support were able to 497 
forego support by Last Assessment, and 89% who were free of respiratory support at 498 
Baseline remained so over the study. These results are consistent with those of 499 
previous smaller studies in infants and young children (n=11; age: 2 wk–3 y) and in 500 
Japanese patients with HPP (n=13; median [min, max] age at Baseline: 91 d [0 d, 34 y]) 501 
(17,18,23). 502 
 503 
Nine deaths occurred in this study, mostly attributed to underlying HPP disease. The 504 
majority of deaths (78%) were radiographic “nonresponders.” One death, which was 505 
attributed to pneumonia, was considered by the investigator to be possibly related to 506 
asfotase alfa. In a prior survival analysis, which included data from some patients in the 507 
current study and other asfotase alfa studies, treatment significantly (P<.0001) improved 508 
survival among patients with perinatal and infantile HPP; survival was 95% at age 1 509 
year and 84% at age 5 years but only 42% and 27%, respectively, among historical 510 
controls (14). 511 
 512 
Asfotase alfa was generally well tolerated, with an overall safety profile consistent with 513 
that observed previously (14,17,23). All patients experienced 1 TEAE; most were mild 514 
or moderate in severity and assessed as unrelated to study drug. Less than 10% of 515 
patients experienced serious AEs that were considered treatment related. The majority 516 
(64%) of treatment-related serious AEs were ISRs or IARs. Clinicians should be aware 517 
of strategies to minimize or prevent ISRs, such as proper injection technique, as well as 518 
management options for reactions requiring treatment (24). Post-Baseline elevated 519 
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calcium levels were considered clinically significant in 3 patients, 2 of whom had 520 
clinically significant elevations at Baseline. Three patients had clinically significant 521 
hypocalcemia during the study. Previous reports discussed the role of dietary calcium 522 
restriction in the management of HPP before asfotase alfa became available, as many 523 
patients have a history of hypercalcemia (17,23). The improved skeletal mineralization 524 
associated with asfotase alfa increases calcium intake requirements (i.e., hungry bone 525 
syndrome). Hence, supplying sufficient dietary calcium and monitoring serum calcium 526 
and PTH during initial treatment are essential (24). Monitoring urine calcium in relation 527 
to serum calcium and PTH is also important in guiding calcium requirements. 528 
 529 
Anti–asfotase alfa antibodies were identified in 88% of patients during this study, and 530 
67% of these patients tested positive for NAbs. Development of anti-drug antibodies has 531 
been documented in previous clinical studies of asfotase alfa, with no apparent impact 532 
on clinical outcomes (17,25). These data reflect small sample sizes (9–12 patients) and 533 
a short duration of treatment exposure (up to 1 year). The current study, which includes 534 
the largest population to date of asfotase alfa–treated patients, with a median (min, 535 
max) treatment duration of 2.3 (0.02, 5.8) years, showed no clear relationship between 536 
the presence of these antibodies and AEs. A post hoc analysis suggests that NAb 537 
positive status may be associated with slow radiographic response as assessed by the 538 
RGI-C at Year 1. Unfortunately, anti-drug antibody testing is not yet commercially 539 
available to identify patients who may not be responding to treatment because of the 540 
presence of NAbs. The development of NAbs could be associated with the severity of 541 
the disease, as has been observed in other conditions such as infantile-onset Pompe 542 
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disease (26), but to date, the limited data available do not allow us to draw firm 543 
conclusions. A recent case report found that the development of NAbs (% inhibition: 544 
40.4%) in a patient with HPP treated with asfotase alfa for 2.5 years was associated 545 
with loss of efficacy and that immune tolerance induction therapy and a 1-month 546 
discontinuation of asfotase alfa successfully restored treatment efficacy within 6 months 547 
(27). Currently, anti-drug antibody testing is available for patients enrolled in the Global 548 
HPP Registry (NCT02306720; EUPAS13514), which will also allow for the collection of 549 
data to further understand the impact of NAbs on the efficacy and safety of asfotase 550 
alfa. 551 
 552 
Generally, RGI-C “nonresponders” at Year 1 represent a subgroup of patients with more 553 
severe HPP at Baseline, evidenced by narrower chest walls (i.e., smaller chest 554 
circumference), greater requirements for mechanical ventilation, and a higher proportion 555 
of deaths. Levels of TNSALP substrates (PPi and PLP) and serum calcium were also 556 
higher in “nonresponders.” These characteristics should be considered when 557 
determining dosing for patients with severe perinatal HPP. It should also be considered 558 
that patients with severe disease may have delayed response to treatment or, in some 559 
cases, limited response to treatment due to serious preexisting complications of HPP 560 
such as severe hypomineralization or lung hypoplasia. 561 
 562 
A limitation of this study was the heterogeneity of study patients, as some patients had 563 
life-threatening perinatal disease. In addition, treatment was initiated at various ages, 564 
making comparisons difficult. Statistical analyses also did not correct for multiplicity or 565 
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confounding variables. Lastly, in our post hoc “responder” analysis, although there were 566 
some patients who had “minimal” radiographic improvements, as a result of our strict 567 
definition of “responders” (RGI-C score ≥+2), these patients were included in the 568 
“nonresponder” group. Accordingly, 9 patients in the “nonresponder” group, included 569 
based on their RGI-C scores at Year 1, had scores ≥+1 to <+3 at Last Assessment, 570 
indicating minimal or substantial healing. 571 
 572 
CONCLUSIONS 573 
Most infants and young children with HPP treated with asfotase alfa showed sustained 574 
improvements in HPP-related skeletal manifestations, respiratory function, and growth. 575 
Asfotase alfa was generally well tolerated. A subgroup of the study patients with very 576 
severe disease at Baseline were classified here as radiographic “nonresponders.” 577 
These patients should be closely monitored for therapeutic response, with dose 578 
adjustments and additional therapeutic measures considered, as necessary. 579 
  580 
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LEGENDS 733 
Figure 1. Patient disposition. 734 
aAll patients who received any asfotase alfa, regardless of whether they were lost to 735 
follow-up or dropped out of the study. 736 
bAll patients from the full analysis set who did not have any major protocol deviations 737 
deemed to potentially influence treatment effect. 738 
c1 patient did not meet the eligibility criteria and had incorrect administration of study 739 
drug. 740 
dConsidered possibly related to study drug treatment in 1 patient. 741 
 742 
Figure 2. Median RGI-C scores over time in infants and children with HPP treated with 743 
asfotase alfa. Patients with RGI-C scores of ≥+2 were classified as “responders.” RGI-C 744 
scale: −3=severe worsening of HPP-related skeletal manifestations; −2=moderate 745 
worsening; −1=minimal worsening; 0=no change; +1=minimal healing; +2=substantial 746 
healing; +3=complete or near complete healing. 747 
aMonth 6 and Year 1 values differ from those in the text for the primary efficacy 748 
measure because no imputation of missing values was performed. 749 
bLast Assessment was defined as the latest post-Baseline assessment on treatment 750 
(within 5 days after end of treatment) with a nonmissing value for each patient; overall 751 
median (min, max) treatment duration was 2.3 (0.02, 5.8) years. 752 
cAll patients were included in the full analysis population; the decreasing n is due to the 753 
number of patients on treatment at end of study or because assessments may not have 754 
been done at each time point. 755 
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*P<.01 based on Wilcoxon signed-rank test comparing median change to 0. 756 
HPP=hypophosphatasia; RGI-C=Radiographic Global Impression of Change. 757 
 758 
Figure 3. Median change from Baseline in RSS scores over time in infants and children 759 
with HPP treated with asfotase alfa. 760 
aLast Assessment was defined as the latest post-Baseline assessment on treatment 761 
(within 5 days after end of treatment) with a nonmissing value for each patient; overall 762 
median (min, max) treatment duration was 2.3 (0.02, 5.8) years. 763 
bAll patients were included in the full analysis population; the decreasing n is due to 764 
number of patients on treatment at the end of study or because assessments may not 765 
have been done at each time point. 766 
*P<.05 based on Wilcoxon signed-rank test comparing median change to 0. 767 
HPP=hypophosphatasia; RSS=Rickets Severity Scale. 768 
 769 
Figure 4. Median (min, max) Z-scores for (A) length/height and (B) weight over time in 770 
infants and children with HPP treated with asfotase alfa. 771 
aLast Assessment was defined as the latest post-Baseline assessment on treatment 772 
(within 5 days after end of study treatment) with a nonmissing value for each patient; 773 
overall median treatment duration was 2.3 (0.02, 5.8) years. 774 
bAll patients were included in the full analysis population; the decreasing n is due to the 775 
number of patients on treatment at the end of study or because assessments may not 776 
have been done at each time point. 777 
*P<.05 based on Wilcoxon signed-rank test comparing median change to 0. 778 
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HPP=hypophosphatasia; SD=standard deviation. 779 
  780 
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Table 1. Baseline Demographic and Clinical Characteristics 781 
Baseline Characteristic 
Enrolled Patients 
N=69 
Age at enrollment, mo, median (min, max) 16.0 (0.3, 72.2) 
Sex, n (%)  
Male 33 (48) 
Race, n (%)  
White 54 (78) 
Asian 7 (10) 
Other 3 (4) 
Unknown 5 (7) 
Age at first signs of HPP, mo  
Median (min, max) 1.0 (0, 5.5) 
HPP-specific medical history, n (%)  
Abnormally shaped chest 58 (84) 
History of respiratory compromise (up to and including 
respiratory failure)a 
46 (67) 
Seizures 17 (25) 
Difficulty gaining weight, failure to thrive, and/or difficulty 
eating/swallowing 
60 (87) 
Hypercalcemia 61 (88) 
Nephrocalcinosis 37 (54) 
Fractures and/or delayed fracture healing 21 (30) 
Length/height Z-score n=67 
Median (min, max) −2.7 (−10.0, 1.0) 
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Baseline Characteristic 
Enrolled Patients 
N=69 
Weight Z-score n=68 
Median (min, max) −2.5 (−24.0, −0) 
RSS score n=67 
Median (min, max) 4.0 (0.0, 10.0) 
ALP, U/L [normal range: 60–370 U/L]b n=65 
Median (min, max) 20 (18, 122) 
PPi, μM [normal range: 1.3–5.7 µM] n=65 
Median (min, max) 6.3 (2.7, 13.3) 
PLP, ng/mL [normal range: 11.8–68.4 ng/mL]c n=60 
Median (min, max) 521 (48, 24600) 
Calcium, mmol/L [normal ranges: 2.25–2.74 mmol/L (age: ≤2 y); 
2.1–2.57 mmol/L (age: >2 y)] 
n=65 
Median (min, max) 2.6 (1.8, 4.0) 
aRespiratory compromise was defined as respiratory signs/symptoms that required 782 
institution of respiratory support measure(s), required medication(s) for management of 783 
symptom(s), and/or were associated with other respiratory complications (e.g., 784 
pneumonia, respiratory tract infection). 785 
bNormal range for ALP activity per ARUP Laboratories (University of Utah, Salt Lake 786 
City, UT) varies by age: 0–30 days: 60–320 U/L; 1–11 months: 70–350 U/L; 1–3 years: 787 
125–320 U/L; 4–6 years: 150–370 U/L. Normal range also varies by sex in patients 788 
older than 10 years of age. 789 
cMedian (min, max) concentration for patients receiving vitamin B6 supplementation 790 
before dosing (n=14) was 9960 (65, 24600) ng/mL and for those patients not receiving 791 
vitamin B6 supplementation before dosing (n=46) was 417 (48, 13100) ng/mL. 792 
ALP=alkaline phosphatase; HPP=hypophosphatasia; PPi=inorganic pyrophosphate; 793 
PLP=pyridoxal 5'-phosphate. 794 
  795 
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Table 2. Treatment-Emergent Adverse Events Occurring in >20% of Patients—796 
Safety Analysis Set 797 
TEAEa Patients, n (%)b 
Pyrexia  47 (68) 
Tooth loss 41 (59) 
Injection site erythema 33 (48) 
Vomiting 31 (45) 
Diarrhea 20 (29) 
Craniosynostosis 19 (28) 
Upper respiratory tract infection 19 (28) 
Nasopharyngitis 18 (26) 
Gastroenteritis 17 (25) 
Cough 17 (25) 
Respiratory tract infection 16 (23) 
Constipation 16 (23) 
Pneumonia 14 (20) 
aAdverse events coded using MedDRA Version 13.0. 798 
bPatient percentages are based on the total number of patients in the treatment group 799 
(N=69). 800 
TEAE=treatment-emergent adverse event. 801 
  802 
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Table 3. Comparison of Baseline Characteristics and Outcomes in Radiographic 803 
“Responders” vs. “Nonresponders”*—Full Analysis Set 804 
 
“Responders”  
(n=50) 
“Nonresponders” 
(n=19) P Value 
Disposition    
Completed study, n (%) 47 (94) 13 (68) .0105 
Discontinued, n     
Withdrawal by parents 1 2  
Adverse event 2 4  
Characteristics    
Age at enrollment, mo, median (min, max) 21.0 (0, 71.4) 8.9 (0.4, 71.7) .2318 
Male, n (%) 25 (50) 8 (42) .5997 
Age at HPP onset, mo, median (min, max) 1.0 (0, 5.5) 1.0 (0, 5.0) .1164 
Time from HPP diagnosis to treatment, 
mo, median (min, max) 
20.3 (0, 67.8) 8.1 (0.3, 67.3) .3753 
Weight Z-score n=49 n=19  
Median (min, max) −2.3 (−7.8, −0.04) −2.7 (−23.8, −0.3) .3930 
Length Z-score n=48 n=19  
Median (min, max) −2.6 (−8.3, 0.9) −3.5 (−10.1, −0.3) .0345 
Chest circumference, cm n=47 n=19  
Median (min, max) 42.5 (32.0, 56.0) 37.0 (27.5, 51.5) .0261 
Race    
Asian, n (%) 5 (10.0) 2 (10.5) 1.0000 
White, n (%) 38 (76.0) 16 (84.2)  
Multiple, n (%) 1 (2.0) 0  
Other, n (%) 2 (4.0) 0  
Unknown/not reported, n (%) 4 (8.0) 1 (5.3)  
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“Responders”  
(n=50) 
“Nonresponders” 
(n=19) P Value 
Laboratory Parameters, median (min, max)   
ALP, U/L n=47 n=18  
 23 (18, 122) 18 (18, 50) .0513 
Calcium, mmol/L n=47 n=18  
 2.5 (1.8, 3.6) 2.6 (2.3, 4.0) .0204 
PLP, ng/mL n=43 n=17  
 429.0 (65.1, 
24100.0) 
1300.0 (47.5, 
24600.0) 
.0403 
PPi, µM n=46 n=19  
 5.9 (2.7, 12.5) 7.1 (3.6, 13.3) .0427 
Magnesium, mmol/L  n=47 n=18  
 0.9 (0.6, 1.2) 0.9 (0.6, 1.1) .6433 
Phosphate, mmol/L n=47 n=18  
 2.0 (1.2, 2.5) 2.0 (0.9, 2.7) .7918 
Parathyroid hormone, pmol/L  n=34 n=14  
 1.5 (0.6, 5.4) 0.6 (0.6, 6.7) .7302 
ALPL Gene Polymorphism, n (%) n=45 n=17 .6634 
Compound heterozygous  31 (69) 13 (77)  
Heterozygous 8 (18) 1 (6)  
Homozygous  6 (13) 3 (18)  
Disease Characteristics, n (%)    
Respiratory compromise 33 (66) 12 (63) 1.000 
Rachitic chest 49 (98) 17 (90) .1817 
B6-responsive seizures 11 (22) 8 (42) .1320 
Abnormally shaped chest  39 (78) 13 (68) .5327 
High serum calcium 35 (70) 14 (74) 1.000 
Nephrocalcinosis 25 (50) 12 (63) .4208 
Mean baseline RSS (SD) 4.7 (3.1) 4.8 (3.5) .9833 
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“Responders”  
(n=50) 
“Nonresponders” 
(n=19) P Value 
Respiratory Characteristics     
Fraction of inspired oxygen, % n=12 n=7  
Median (min, max) 29.0 (21.0, 50.0) 25.0 (21.0, 54.0) .3500 
Inspiratory pressure, cm H2O n=8 n=5  
Median (min, max) 25.5 (0.4, 31.0) 24.0 (15.0, 32.0) .6601 
Expiratory pressure, cm H2O n=9 n=7  
Median (min, max) 7.0 (5.0, 12.0) 6.0 (5.0, 8.0) .2726 
Respiratory support type, n (%)    
No support  35 (70) 10 (53) .5079 
Mechanical ventilation 8 (16) 5 (26)  
Supplemental oxygen 4 (8) 2 (11)  
CPAP 2 (4) 2 (11)  
Other 1 (2) 0 (0)  
Respiratory support duration, h n=14 n=8  
Median (min, max) 24 (8, 24) 24 (24, 24) .4497 
Treatment Exposure    
Dosing frequency, n (%)   .6642 
Always received 3 times/wk 46 (92) 17 (90)  
Ever received >3 times/wk 4 (8) 2 (11)  
Last dose received, mg/kg/wk, median 
(min, max) 
4.0 (2, 12) 5.7 (2, 11) .2924 
Treatment duration, y, median (SD) 2.3 (0.6, 8.8) 1.9 (0.02, 4.2) .1342 
ADA/NAbs    
Positive ADA status, n (%)    
Month 6 34 (71) 12 (80) .7400 
Year 1 28 (64) 9 (90) .1411 
Ever 45 (90) 15 (83) .4279 
Positive NAb status, n (%)    
Month 6 10 (30) 6 (50) .2963 
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“Responders”  
(n=50) 
“Nonresponders” 
(n=19) P Value 
Year 1 8 (29) 5 (56) .2293 
Ever 29 (64) 11 (73) .7529 
Last Assessment 9 (20) 9 (60) .0074 
NAb by percent inhibition, median (min, 
max) 
   
Month 6 2.4 (−1.7, 90.3) 5.4 (−0.5, 88.5) .1820 
Year 1 2.5 (−6.2, 63.5) 4.7 (−3.5, 93.8) .3046 
Death    
Number of deaths on study, n (%) 2 (4) 7 (37) .0012 
RGI-C Scores    
RGI-C score at Last Assessment n=50 n=17  
Median (min, max) +2.7 (−2.7, +3.0) +1.0 (−1.7, +2.7) <.0001 
Category, n (%)    
−3 to <−2 2 (4) 0  
−2 to <−1 0 1 (6)  
−1 to <0 1 (2) 4 (24)  
0 to <+1 0 3 (18)  
+1 to <+2 3 (6) 4 (24)  
+2 to <+3 40 (80) 5 (29)  
+3 4 (8) 0  
ADA=anti-drug antibodies; ALP=alkaline phosphatase; CPAP=continuous positive 805 
airway pressure; HPP=hypophosphatasia; NAb=neutralizing antibody; RGI-C= 806 
Radiographic Global Impression of Change; PLP=pyridoxal 5'-phosphate; PPi=inorganic 807 
pyrophosphate. 808 
*RGI-C “responders”: mean score ≥+2 at Year 1. 809 
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